Summit Therapeutics Inc.

General ticker "SMMT" information:

  • Sector: Health Care
  • Industry: Biotechnology
  • Capitalization: $15.9B (TTM average)

Summit Therapeutics Inc. does not follow the US Stock Market performance with the rate: -2.7%.

Estimated limits based on current volatility of 4.1%: low 16.64$, high 18.05$

Factors to consider:

  • Total employees count: 159 as of 2024
  • Top business risk factors: Operational and conduct risks, Economic downturns and volatility, Third-party risks, Regulatory and compliance, Intellectual property risks
  • Current price 17.3% above estimated high
  • Earnings for 6 months up through Q2 are below our estimates

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2024-12-31 to 2026-12-31

  • 2024-12-31 to 2025-12-31 estimated range: [7.93$, 24.83$]
  • 2025-12-31 to 2026-12-31 estimated range: [4.34$, 14.52$]

Similar symbols

Short-term SMMT quotes

Long-term SMMT plot with estimates

Financial data

YTD 2022-12-31 2023-12-31 2024-12-31
Operating Revenue $0.70MM $0.00MM $0.31MM
Operating Expenses $60.34MM $89.74MM $226.31MM
Operating Income $-59.63MM $-89.74MM $-226.00MM
Non-Operating Income $-19.15MM $-526.14MM $4.68MM
Interest Expense $4.40MM $16.46MM $8.69MM
R&D Expense $52.00MM $59.47MM $165.78MM
Income(Loss) $-78.78MM $-615.87MM $-221.31MM
Taxes $0.00MM $-0.95MM $0.00MM
Profit(Loss)* $-78.78MM $-614.93MM $-221.31MM
Stockholders Equity $126.65MM $77.69MM $388.75MM
Assets $664.17MM $202.95MM $435.56MM
Operating Cash Flow $-41.58MM $-76.76MM $-142.11MM
Capital expenditure $0.62MM $0.13MM $0.14MM
Investing Cash Flow $-0.62MM $-587.77MM $-205.34MM
Financing Cash Flow $620.24MM $86.51MM $381.23MM
Earnings Per Share** $-0.41 $-0.99 $-0.31

* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.